Drug Profile
Putrescine-D-YiAbeta11
Latest Information Update: 04 Oct 2001
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Diamines
- Mechanism of Action Amyloid inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 04 Oct 2001 No-Development-Reported for Alzheimer's disease in USA (Unknown route)
- 17 Dec 1998 New profile
- 17 Dec 1998 Preclinical development for Alzheimer's disease in USA (Unknown route)